TELOGENOMICS
Precision Medicine

NEWS RELEASE

Telo Genomics Announces Investor Relations Agreement

Toronto, Ontario, August 11, 2021 – Telo Genomics Corp. (TSX-V: TELO) (the **"Company"** or **"TELO")** is pleased to announce that it has engaged Terry Bramhall ("Bramhall") to perform services for the Company, including investor relations activities, as defined in accordance with the polices of the TSX Venture Exchange ("TSXV") and applicable securities laws.

Pursuant to an agreement entered into with Bramhall on July 28, 2021, Bramhall will receive a cash fee of $2,000 per month over a period of six months for a total of $12,000. The Company has granted Bramhall 50,000 stock options, with each option exercisable into one common share at an exercise price of $0.50 per share, vesting quarterly over a 12-month period. All vested options shall be eligible for exercise for a period ending on the earlier if (i) 2 years from the date of the grant and (ii) 90 days following termination of the agreement.

The stock option grant and agreement with Bramhall are subject to the approval of the TSX Venture Exchange.

About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.

For further information, please contact:

Hugh Rogers, Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView™ platform to deliver personalized medicine resulting in better *treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.*

MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7
Tel: 416-673-8487 email: info@telodx.com